论文部分内容阅读
目的探讨脱氧核苷酸钠(Sodium Deoxyribonucleotide,SD)治疗小儿支原体肺炎合并肝损伤(Pediatric liver injury,PLI)的临床疗效及安全性。方法开放性非随机临床对照研究,2011年2月～2013年2月我科收治的小儿支原体肺炎合并PLI患者61例,在综合治疗的基础上予以SD 50mg ivgtt,每日一次。治疗4周后比较治疗前后患者肝功能指标等有无差别及治疗期间的不良反应发生率。结果SD治疗4周后,患儿肝功能指标ALT、AST及GGT较治疗前明显下降,差别有统计学意义(P均<0.05);治疗期间未见明显不良反应。结论 SD治疗小儿肝损伤临床疗效确切,无明显不良反应。
Objective To investigate the clinical efficacy and safety of sodium deoxyribonucleotide (SD) in the treatment of pediatric mycoplasma pneumonia complicated with liver injury (PLI). Methods Open non-randomized clinical controlled study, 61 cases of pediatric mycoplasma pneumonia complicated with PLI admitted to our department from February 2011 to February 2013 were treated with SD 50 mg ivgtt once a day on the basis of comprehensive treatment. After 4 weeks of treatment, the patients’ liver function indexes were compared before and after treatment, and the incidence of adverse reactions during treatment was compared. Results After 4 weeks of treatment, the ALT, AST and GGT of liver function in children were significantly lower than those before treatment (all P <0.05). No obvious adverse reactions were found during the treatment. Conclusion SD treatment of pediatric liver injury clinical curative effect, no obvious adverse reactions.